Advaxis Being Overlooked in Scorching Cancer Immunotherapy Field

February 24, 2015 • Analysis, Free • Tags: , , , , ,

Immunotherapies and combination therapies have been the recent rage in oncology. Just yesterday, Bristol-Myers Squibb (BMY) acquired Flexus Biosciences for a potential $1.25 billion, including $800 million upfront and up to $450 million in milestones. That’s a lot of money the giant pharma paid for the potential of Flexus’ technology and preclinical data.

Bristol is betting that Flexus’ immunotherapeutic approach across several tumor types could show traction with the combination of the company’s own biologic checkpoint agents. Flexus’ lead preclinical small molecule ID01-inhibitor is targeting a 2H 2015 IND filing.

Flexus shareholders will retain all non-IDO/TDO assets, including the lead Phase I FLT3 and CDK 4/6 inhibitor. BMY’s preclinical acquisition shows just ho...

RESTRICTED CONTENT

To Continue LOG IN or REGISTER

Tags: , , , , ,